The Dow Spikes as Citigroup Settles for $7 Billion, Beats on Earnings

Citigroup tops earnings projections after agreeing to a major deal with the Department of Justice, while Abbott Labs and Mylan agree to a huge sale.

Jul 14, 2014 at 2:30PM

Stocks have boomed to kick off the new week as the Dow Jones Industrial Average (DJINDICES:^DJI) has gone on a tear since the opening bell sounded. As of 2:15 p.m. EDT, the Dow has jumped 125 points, with all but a handful of its 30 member stocks in the green so far. Today's biggest stock stories have come from outside the Dow Jones, however, after Citigroup (NYSE:C) walloped Wall Street earnings forecasts and Abbott Labs (NYSE:ABT) and generic-drug maker Mylan (NASDAQ:MYL) agreed to a big deal. Let's catch up on what you need to know.

Citi keeps earnings season rolling

Citibank Mosco

Citibank in Moscow, Russia. Source: Wikimedia Commons.

Citigroup topped earnings expectations in its second-quarter results, pushing the bank stock higher by 3% on the day. The company's $1.24 in adjusted per-share net earnings soundly smashed average analyst projections of $1.05, and trading revenue at Citigroup fell less than expected, declining 16% year over year after company leadership had projected a much wider loss.

However, Citigroup's $7 billion settlement with the Department of Justice has dominated the news on this big bank today. The company's agreement with the government will resolve potential lawsuits against the bank regarding the sale of mortgage securities before the 2008 financial crisis. Citi noted that the deal, which includes a cash penalty of $4 billion, cost the company $3.8 billion in pre-tax earnings for the second quarter. That slammed the firm's unadjusted earnings today -- Citi managed net income of only $181 million, a giant drop-off from the quarter a year ago -- but the settlement will allow the bank and its investors to move on from the storm cloud of government investigation.

Elsewhere around the market today, Abbott Labs is making waves around Wall Street, although the health care stock has climbed just 0.8% on the day. Abbott agreed to sell part of its established drug business to generic-drug giant Mylan in a deal worth more than $5 billion. It's an important step forward for Abbott and its investors, as the company's generic-drug business has been a drag on growth lately. In the first quarter, the unit saw sales decline by more than 6% year over year, hit hard by currency exchanges, as Abbott's generics business operates solely outside of the U.S.

Even on operational growth, however, the business saw sales slip by nearly 1% year over year, making it Abbott's second-worst-performing unit for the quarter after nutritionals, which were largely affected by a supplier recall. In the long term, the generics business isn't a growth driver for Abbott or its shareholders, and selling off part of the unit will allow the company to focus on higher-growth areas such as diagnostics and nutrition.

It's also a great deal for Mylan, however. The company plans to combine its existing business with the assets it picked up from Abbott to launch a new company incorporated in the Netherlands. There, Mylan projects it will lower its tax rate from 25% to around 21% in the first full year of operations, with further tax reductions likely to come down the road. Mylan expects the purchase to add nearly $2 billion worth of revenue to the company's portfolio once the deal is closed, helping the company gain more traction outside of the U.S. In all, it's a sound deal for both parties -- and for shareholders of each.

Bank of America + Apple? This device makes it possible.
Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out, and some early viewers are claiming its destined to change everything from banking to health care. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here

Dan Carroll has no position in any stocks mentioned. The Motley Fool owns shares of Citigroup. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information